JH Health

JH Health is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for metabolic and chronic diseases, with a primary focus on obesity, diabetes, and NASH. The company's lead candidate, JH08, is a long-acting triple agonist targeting the GLP-1, GIP, and glucagon receptors, currently undergoing Phase 2 clinical trials for weight management and glycemic control. JH Health leverages its proprietary peptide engineering platform and small molecule discovery capabilities to build a robust pipeline of multi-target agonists and metabolic regulators. Headquartered in Beijing with research facilities in San Diego, the company aims to address the global burden of metabolic health through next-generation endocrine therapies.